Revolution Medicines books $197.6 million in first Rasonque sales

Revolution Medicines lost $1.90 a share in the third quarter, less than the $2.46 expected. Its pancreatic cancer drug Rasonque brought in $197.6 million of net product revenue in about five weeks after its August 26 U.S. approval, against about $24.0 million expected.

The results

Q3 2026
+22.8%
Earnings
+724.4%
Revenue
−11.0%
The stock
Earnings per share
Expected -$2.46
-$1.90
Revenue
Expected $23.96M
$197.56M

What the company expects

Revolution Medicines reiterated its full-year 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion, including $270 million to $290 million of non-cash stock-based compensation. It expects global enrollment in the RASolute 303 pancreatic cancer trial to finish in the first half of 2027 and an initial readout of the RASolve 301 lung cancer trial in 2027.
Results for Q3 2026, released on November 4, after the close. Expected: average of analysts' forecasts.

AI analysis

Nov 4
With TrueWallet Pro
What drove the quarter, what it changes for the stock, and what it does not say. Upgrade to Pro from the TrueWallet app.

The whole feed is waiting

Sign in to read every post and follow wallets.
Sign in